Inhaled insulin - does it become reality?

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 6, 2008, Pages 81-113

  Siekmeier, R ^a,c   Scheuch, G ^b  

^a Federal Institute for Drugs and Medical Devices BfArM   (Germany)

^b Activaero GmbH   (Germany)

^c Bundesinstitut für Arzneimittel und Medizinprodukte ^*  (Germany)

Author keywords

Aerosol therapy; Inhalation; Insulin; Systemic treatment

Indexed keywords

APROTININ; BACITRACIN; GLUCOSE; HEMOGLOBIN A1C; LIPOSOME; MICROSPHERE; NAFAMSTAT; NEUTRAL INSULIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN; SOYBEAN TRYPSIN INHIBITOR; ANTIDIABETIC AGENT; DRUG CARRIER; INSULIN;

ACCURACY; AEROSOL; AREA UNDER THE CURVE; ASTHMA; BLISTER PACK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MARKETING; DRUG PACKAGING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG UPTAKE; DYSPNEA; EMPHYSEMA; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HYPOGLYCEMIA; INHALER; INSULIN PUMP; INSULIN TREATMENT; LIPODYSTROPHY; LONG TERM CARE; LUNG ALVEOLUS; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; NEBULIZER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; POSTMARKETING SURVEILLANCE; POWDER; POWDER INHALER; REVIEW; SMOKING; SORE THROAT; STATISTICAL SIGNIFICANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA; ABSORPTION; AGING; ANIMAL; BIOAVAILABILITY; DIABETES MELLITUS; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PATIENT ATTITUDE; PHYSIOLOGY;

ABSORPTION; ADMINISTRATION, INHALATION; AGING; ANIMALS; BIOLOGICAL AVAILABILITY; DIABETES MELLITUS; DRUG CARRIERS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOSOMES; MICROSPHERES; PATIENT ACCEPTANCE OF HEALTH CARE; SMOKING;

EID: 64549157603     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2: 198-209.
2. Siekmeier R, Scheuch G. Systemische Therapie mit Aerosolen - Allgemeine Grundlagen zur pulmonalen Verabreichung von Makromolekulen zur systemischen Therapie. Atemw-Lungenkrkh 2005; 31: 374-386.
3. Heinemann L, Pfutzner A, Heise T: Alternative routes of administration as an approach to improve insulin therapy: Update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001; 7: 1327-1351.
4. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 1995; 12: 151-231.
5. Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74.
6. Wolff RK. Safety of inhaled proteins for therapeutic use. J Aerosol Med 1998; 11: 197-219.
7. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7: 49-75.
8. Kohler D, Fleischer W. Medikamente. In Theorie und Praxis der Inhalationstherapie. Köhler D, Fleischer W (eds). Arcis Verlag, Munchen 2000, pp. 71-99.
9. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006; 58: 996-1008.
10. Scheuch G, Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol 2007; 58 (Suppl 5, Pt 2): 615-625.
11. Yu J, Chien YW. Pulmonary drug delivery: Physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst 1997; 14: 395-453.
12. Kohler D. Aerosols for systemic treatment. Lung 1990; 168 (Suppl): 677-684.
13. Siekmeier R, Scheuch G. Systemische Therapie mit Aerosolen. Beispiele zur pulmonalen Verabreichung von Makromolekulen zur systemischen Therapie. Atemw-Lungenkrkh 2005; 31: 391-410.
14. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003; 42: 1107-1128.
15. Hussain A, Arnold JJ, Khan MA, Ahsan F. Absorption enhancers in pulmonary protein delivery. J Control Release 2004; 94: 15-24.
16. Song Y, Wang Y, Thakur R, Meidan VM, Michniak B. Mucosal drug delivery: Membranes methodologies, and applications. Crit Rev Ther Drug Carrier Syst 2004; 21: 195-256.
17. Cryan SA. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 2005; 7: E20-E41.
18. Owens DR. New horizons - Alternative routes for insulin delivery. Nat Rev Drug Discov 2002; 1: 529-540.
19. Wilde MI, McTavish D. Insulin lispro: A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 1997; 54: 597-614.
20. Cefalu WT. Concept, strategies, and feasibility of non-invasive insulin delivery. Diabetes Care 2004; 27: 239-246.
21. Belmin J, Valensi P. Novel drug delivery systems for insulin. Clinical potential for use in the elderly. Drugs Aging 2003; 20: 303-312.
22. Laqueur E, Grevenstuk A. Uber die Wirkung intratrachealer Zufuhrung von Insulin. Klin Wochenschr 1924; 3: 1273-1274.
23. Heubner W, de Jongh SE, Laquer E. Uber Inhalation von Insulin. Klin Wochenschr 1924; 3: 2342-2343.
24. Gänsslen M. Uber Inhalation von Insulin. Klin Wochenschr 1925; 4: 71.
25. Wigley FW, Londono JH, Wood SH, Ship JC, Waldman RH. Insulin across respiratory mucosae by aerosol delivery. Diabetes 1971; 20: 552-556.
26. Elliott RB, Edgar BW, Pilcher CC, Quested C, McMaster J. Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J 1987; 23: 293-297.
27. Kohler D, Schluter KJ, Kerp L, Matthys H. Nicht radioaktives Verfahren zur Messung der Lungenpermeabilitat. Inhalation von Insulin. Atemw-Lungenkrkh 1987; 13: 230-232.
28. Laube BL, Georgopoulos A, Adams GK. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic subjects. JAMA 1993; 269: 2106-2109.
29. Gonda I. The ascent of pulmonary drug delivery. J Pharm Sci 2000; 89: 940-945.
30. Guntur VP, Dhand R. Inhaled insulin: Extending the horizons of inhalation therapy. Respir Care 2007; 52: 911-922.
31. Charlish P. Therapeutic focus - How would you like your insulin. Bio Partnering Today 2006; 6-9.
32. de Galan BE, Simsek S, Tack CJ, Heine RJ. Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus. Neth J Med 2006; 64: 319-325.
33. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005; 50: 1161-1176.
34. Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev 2006; 58: 1061-1075.
35. Pearson J. Inhalation technologies - A breath of fresh air. Drug Delivery Report 2006; Spring/Summer: 19-21.
36. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43: 781-801.
37. Sakagami M, Byron PR. Respirable microspheres for inhalation. The potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin Pharmacokinet 2005; 44: 263-277.
38. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycaemic effect. J Control Release 1999; 62: 279-287.
39. Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-1871.
40. Brown L, Rashba-Step J, Scott T. Pulmonary delivery of novel insulin microspheres. In Respiratory Drug Delivery XIII. Dalby RN, Byron PR, Peart J, Farr SJ (eds), Davis Horwood International Publishing, Raleigh NC, 2002, pp. 431-433.
41. Surendrakumar K, Martyn GP, Hodgers ECM, Jansen M, Blair JA. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release 2003; 91: 385-394.
42. Pfutzner A, Mann AE, Steiner SS. Technosphere/Insulin - a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002; 4: 589-594.
43. Steiner S, Pfutzner A, Wilson BR, Harzer O, Heinemann L, Rave K. Technosphere/Insulin - proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002; 110: 17-21.
44. Garcia-Contreras L, Morcol T, Bell SJD, Hickey AJ. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS Pharm Sci 2003; 5: E9.
45. Bhat M. Development of a novel spray-drying technique to produce particles for aerosol delivery. In Respiratory Drug Delivery XIII. Dalby RN, Byron PR, Peart J, Farr SJ (eds), Davis Horwood International Publishing, Raleigh NC, 2002, pp. 427-429.
46. Blair J, Coghlan D, Langner E, Jansen M, Askey-Sarvar A. Sustained delivery of insulin via the lung using Solidose technology. In Respiratory Drug Delivery XIII. Dalby RN, Byron PR, Peart J, Farr SJ (eds), Davis Horwood International Publishing, Raleigh NC, 2002, pp. 411-414.
47. Hrkash J, Batycky R, Chen D. AIR insulin: Complete diabetes therapy via inhalation of fast-acting and slow-acting dry powder aerosols. Diabetes 2000; 49: A9 (Abstract).
48. Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006; 113: 9-14.
49. Rudt S, Muller R. In vitro phagocytosis assay of nanoparticles and microparticles by chemiluminescence. 1. Effect of analytical parameters, particle size and particle concentration. J Control Release 1992; 22: 263-271.
50. Edwards DA, Dunbar C. Bioengineering of therapeutic aerosols. Annu Rev Biomed Eng 2002; 4: 93-107.
51. Okamoto H, Todo H, Iida K, Danjo K. Dry powders for pulmonary delivery of peptides and proteins. Kona 2002; 20: 71-83.
52. Johansson F, Hjertberg E, Eirefelt S, Tronde A, Hultkvist Bengtsson U. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur J Pharm Sci 2002; 17: 63-71.
53. Komada F, Iwakawa S, Yamamoto N, Sakakibara H, Okumura K. Intratracheal delivery of peptide and protein agents: Absorption from solution and dry powder by rat lung. J Pharm Sci 1994; 83: 863-867.
54. Okumura K, Iwakawa S, Yoshida T, Seki T, Komada F. Intratracheal delivery of insulin. Absorption from solution and aerosol by rat lung. Int J Pharm 1992; 88: 63-73.
55. Yamamoto A, Umemori S, Muranishi S. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J Pharm Pharmacol 1994; 46: 14-18.
56. Heinemann L, Klappoth W, Rave H, Hompesch B, Linkeschowa R, Heise T. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 2000; 23: 1343-1347.
57. Todo H, Okamoto H, Iida K, Danjo K. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int J Pharm 2001; 220: 101-110.
58. Li Y, Mitra AK. Effects of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Pharm Res 1996; 13: 76-79.
59. Liu F, Shao Z, Kildsig DO, Mitra AK. Pulmonary delivery of free and liposomal insulin. Pharm Res 1993; 10: 228-232.
60. Shao Z, Li Y, Mitra AK. Cyclodextrins as mucosal absorption promoters of insulin. III: Pulmonary route of delivery. Eur J Pharm Biopharm 1994; 40: 283-288.
61. Shen ZC, Cheng Y, Zhang Q, Wei SL, Li RC, Wang K. Lanthanides enhance pulmonary absorption of insulin. Biol Trace Elem Res 2000; 75: 215-225.
62. Garcia-Contreras L, Sarubbi D, Flanders E, Smart J, Newcomer C, Hicke AJ. Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. Pharm Res 2001; 18: 1685-1693.
63. Suarez S, Garcia-Contreras L, Sarubbi D et al. Facilitation of pulmonary insulin absorption by H-MAP: Pharmacokinetics and pharmacodynamics in rats. Pharm Res 2001; 18: 1677-1684.
64. Morimoto K, Uehara Y, Iwanaga K, Kakemi M. Effects of sodium glycocholate and protease inhibitors on permeability of TRH and insulin across rabbit trachea. Pharm Acta Helv 2000; 74: 411-415.
65. Fukuda Y, Tsuji T, Fujita T, Yamamoto A, Muranishi S. Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors. Biol Pharm Bull 1995; 18: 891-894.
66. Sakagami M. Insulin disposition in the lung following oral inhalation in humans. A meta- analysis of its pharmacokinetics. Clin Pharmacokinet 2004; 43: 539-552.
67. Farr SJ, McElduff A, Mather LE et al. Pulmonary insulin administration using the AERx system: Physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000; 2: 185-197.
68. Perera AD, Kapitza C, Nosek L et al. and metabolic effect of inhaled insulin. Intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002; 25: 2276-2281.
69. Heise T, Scharling B, Bellaire S. Dose-response of pulmonary insulin with the AERx insulin diabetes management system in healthy subjects. Diabetologia 2001; 44 (Suppl 2): A212 (Abstract).
70. Fishman RS, Guinta D, Chambers F. Insulin administration via the Aerodose™ inhaler: Comparison to subcutaneously injected insulin. Diabetes 2000; 49 (Suppl 1): A9 (Abstract).
71. Chien JY, Wise SD, Sathirakul K. Time action profile of inhaled insulin via Spiros dry powder inhaler is consistent among user inhalation techniques. Diabetologia 2001; 44 (Suppl 2): A211 (Abstract).
72. Rave K, Muchmore D, Gonzales C. Inhaled insulin with an improved Spiros® dry powder inhaler: Dose response and time-action profiles. Diabetologia 2001; 44 (Suppl 2): A211 (Abstract).
73. Steiner S, Rave KM, Heise T. Bioavailability and pharmacokinetic properties of inhaled dry powder Technosphere/Insulin. Diabetes 2000; 49 (Suppl 1): A126 (Abstract).
74. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14: 63-72.
75. Brunner GA, Balent B, Ellmerer M et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001; 44: 305-308.
76. Kim D, Mudaliar S, Plodkowski R. Dose-response relationships of inhaled and subcutaneous insulin in type 2 diabetic patients. Diabetes 2002; 51 (Suppl 2): A47 (Abstract).
77. Rave KM, Heise T, Pfutzner A. Results of a dose-response study with a new pulmonary insulin formulation and inhaler. Diabetes 2000; 49 (Suppl 1): A75 (Abstract).
78. Barnett AH. Exubera inhaled insulin: A review. Int J Clin Pract 2004; 58: 394-401.
79. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21: 1910-1914.
80. Himmelmann A, Jendle J, Mellen A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 2003; 26: 677-682.
81. Valente AXCN, Langer R, Stone HA, Edwards DA. Recent advances in the development of an inhaled insulin product. Biodrugs 2003; 17: 9-17.
82. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002; 4: 673-682.
83. Gelfand RA, Schwartz S, Horton M. Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus (NIDDM). Diabetes 1998; 47 (Suppl1): A99 (Abstract).
84. Hompesch M, Kapitza C, Scharling B. Intra-subject variability of pulmonary insulin via the AERx® insulin diabetes management system versus subcutaneous insulin. Diabetologia 2001; 44 (Suppl 2): A212 (Abstract).
85. Pfützner A, Heise T, Steiner S. Inhaled Technosphere/Insulin shows a low variability in metabolic action in type 2 diabetic patients. Diabetes 2000; 49 (Suppl 1): A121 (Abstract).
86. Sha S, Becker RHA, Willavise SA. The effect of smoking cessation on the absorption of inhaled insulin (Exubera®). Diabetes 2002; 51 (Suppl 2): A133 (Abstract).
87. Becker RHA, Sha S, Frick AD, Fountaine RJ. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006; 29: 277-282.
88. McElduff A, Mather LE, Kam PC, Clauson P. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx® insulin Diabetes Management system. Br J Clin Pharmacol 2005; 59: 546-551.
89. Henry RR, Mudaliar SRD, Howland WC et al. Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care 2003; 26: 764-769.
90. Henry RR, Mudaliar S, Chu N et al. Young and elderly type 2 diabetic patients inhaling insulin with the AERx® insulin diabetes management system: A pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol 2003; 43: 1228-1234.
91. Jones JG, Minty BD, Lawler P, Hulands GL, Crawley JCW, Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980; 1: 66-68.
92. Minty BD, Jordan C, Jones JG. Rapid improvement in abnormal pulmonary epithelial permeability after stopping cigarettes. Br Med J 1981; 282: 1183-1186.
93. Lehr HA. Microcirculatory dysfunction induced by cigarette smoking. Microcirculation 2000; 7: 367-384.
94. Nieman GF, Clark WR, Paskanik AM, Bredenberg CE, Hakim TS. Unilateral smoke inhalation increases pulmonary blood flow to the injured lung. J Trauma 1994; 36: 617-623.
95. Li XY, Rahman I, Donaldson K, MacNee W. Mechanisms of cigarette smoke induced increased airspace permeability. Thorax 1996; 51: 465-471.
96. Schmekel B, Bos JA, Khan AR, Wohlfart B, Lachmann B, Wollmer W. Integrity of the alveolar- capillary barrier and alveolar surfactant system in smokers. Thorax 1992; 47: 603-608.
97. Miller LG. Cigarettes and drug therapy: Pharmacokinetic and pharmacodynamic considerations. Clin Pharm 1990; 9: 125-135.
98. Attvall S, Fowelin J, Lager I, von Schenck H, Smith U. Smoking induces insulin resistance: A potential link with the insulin resistance syndrome. J Intern Med 1992; 233: 327-332.
99. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YDI, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-1130.
100. Nakanishi N, Nakamura K, Matsuo Y, Suzuki K, Tatara K. Cigarette smoking and risk for impaired fasting glucose and type 2 diabetes in middle-aged Japanese men. Ann Intern Med 2000; 133: 181-191.
101. Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E: Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 3619-3624.
102. Klemp P, Staberg B, Madsbad S, Kolendorf K. Smoking reduces insulin absorption from subcutaneous tissue. Br Med J 1982; 284: 237.
103. Fountaine R, Milton A, Checchio T et al. Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. Br J Clin Pharmacol 2008; 65: 864-870.
104. Davis TME, Davis WA. An assessment of eligibility for inhaled insulin (Exubera). Diabetes Care 2007; 30: 360-361.
105. Mudaliar S, Henry RR. Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease. Diabetes Technol Ther 2007; 9 (Suppl 1): S83-S92.
106. Rave K, de la Pena A, Tibaldi FS et al. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: Pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care 2007; 30: 1777-1782.
107. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M on behalf of the Exubera Phase III Study Group. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006; 29: 1282-1287.
108. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M on behalf of the Exubera Phase III Study Group. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006; 29: 1818-1825.
109. Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M on behalf of the Exubera® Phase 3 Study Group. Long-term tolerability of inhaled human insulin (Exubera®) in patients with poorly controlled type 2 diabetes. Int J Clin Pract 2007; 61: 1614-1625.
110. Ceglia L, Lau J, Pittas AG. Meta-analysis: Efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145: 665-675.
111. DeFronzo RA, Bergenstal RM, Cefalu WT et al. for the Exubera Phase III Study group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial. Diabetes Care 2005; 28: 1922-1928.
112. Rosenstock J, Zinman B, Murphy LJ et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2005; 143: 549-558.
113. Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W for the Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007; 30: 579-585.
114. Black C, Cummins E, Royle P, Philip S, Waugh N. The clinical effectiveness and cost- effectiveness of inhaled insulin in diabetes mellitus: A systematic review and economic evaluation. Health Technol Assess 2007; 11 (33): 1-126.
115. Cefalu WT, Skyler JS, Kourides IA et al. for the Inhaled Insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134: 203-207.
116. Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: A 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004; 27: 162-167.
117. Hollander PA, Blonde L, Rowe R et al. for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-2362.
118. Quattrin T, Belanger A, Bohannon NJV, Schwartz SL for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004; 27: 2622-2627.
119. Skyler JS, Cefalu WT, Kourides IA et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomised proof-of-concept study. Lancet 2001; 357: 331-335.
120. Skyler JS, Weinstock RS, Raskin P et al. the Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6- month, randomized, comparative trial. Diabetes Care 2005; 28: 1630-1635.
121. NDA 21-868/EXUBERA: U.S. package insert, 2006. New York, NY, Pfizer Labs. Available from http://www.pfizer.com/pfizer/download/uspi-exubera.pdf.
122. FDA Med Watch Alert. Exubera (insulin human rDNA origin) Inhalation Powder. Available from http://www.drugs.com/fda/exubera-insulin-human-rdna- origin-inhalation-powder-12372.html.
123. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005; 90: 3287-3394.
124. Stoever JA, Palmer JP. Inhaled insulin and insulin antibodies: A new twist to an old debate. Diabetes Technol Ther 2002; 4: 157-161.
125. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996; 104: 106-110.
126. Lawrence RD. Local insulin reactions. Lancet 1925; 1: 1125-1126.
127. Radermecker RP, Pierard GE, Scheen AJ. Lipodystrophy reactions to insulin. Effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol 2007; 8: 21-28.
128. Ghosh S, Collier A. Inhaled insulins. Postgrad Med J 2007; 83: 178-181.
129. Royle P, Waugh N, McAuley L, McIntyre L, Thomas S. Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2004; CD003890.
130. Hamilton JG. Needle phobia: Aneglected diagnosis. J Fam Pract 1995; 41: 169-175.